Clinical Physiology Institute, National Council Research, Pisa, Italy.
Am J Med Sci. 2012 Jan;343(1):65-70. doi: 10.1097/MAJ.0b013e31822846bd.
There are no studies on the long-term prognostic role of abnormal thyrotropin value in patients with acute cardiac diseases. Aim of the study was to assess the incidence and persistence of risk of cardiac and overall deaths in patients with acute cardiac diseases.
A total of 1026 patients (mean age: 67.7 years) were divided into 4 groups: (1) euthyroid (EU, n=579); (2) subclinical-like hypothyroidism (SLHYPO, n=68); (3) subclinical-like hyperthyroidism (SLHYPER, n=23) and (4) low-triiodothyronine syndrome (LowT3, n=356). Follow-up started from the day of thyroid hormone evaluation (mean follow-up: 30 months). The events considered were cardiac and overall deaths.
Survival rate for cardiac death was lower in SLHYPO and in LT3 than in EU (log rank test; χ(2)=33.6; P < 0.001). Survival rate for overall death was lower in SLHYPO, SLHYPER and LowT3 than in EU (48.3; P < 0.001). After adjustment for several risk factors, the hazard ratio for cardiac death was higher in SLHYPO (3.65; P=0.004) in LowT3 (1.88; P=0.032) and in SLHYPER (4.73; P=0.047). Hazard ratio for overall death was higher in SLHYPO (2.30; P=0.009), in LowT3 (1.63; P=0.017) and in SLHYPER than in EU (3.71; P=0.004). Hazards for SLHYPO, SLHYPER and LowT3 with respect to EU were proportional over the follow-up period.
In patients with acute cardiac disease, a mildly altered thyroid status was associated with increased risk of mortality that remains constant during all the follow-up.
目前尚无研究探讨急性心脏疾病患者促甲状腺激素值异常的长期预后作用。本研究旨在评估急性心脏疾病患者发生心脏和全因死亡的风险及持续性。
共纳入 1026 例患者(平均年龄:67.7 岁),分为 4 组:(1)甲状腺功能正常组(EU),n=579;(2)亚临床甲状腺功能减退症组(SLHYPO),n=68;(3)亚临床甲状腺功能亢进症组(SLHYPER),n=23;(4)低三碘甲状腺原氨酸综合征组(LowT3),n=356。从甲状腺激素评估日开始随访(平均随访:30 个月)。考虑的事件为心脏死亡和全因死亡。
SLHYPO 和 LowT3 组的心脏死亡生存率均低于 EU 组(对数秩检验;χ(2)=33.6;P<0.001)。SLHYPO、SLHYPER 和 LowT3 组的全因死亡生存率均低于 EU 组(48.3;P<0.001)。调整多种危险因素后,SLHYPO(HR=3.65;P=0.004)、LowT3(HR=1.88;P=0.032)和 SLHYPER(HR=4.73;P=0.047)组的心脏死亡风险更高。SLHYPO(HR=2.30;P=0.009)、LowT3(HR=1.63;P=0.017)和 SLHYPER 组的全因死亡风险均高于 EU 组(HR=3.71;P=0.004)。SLHYPO、SLHYPER 和 LowT3 与 EU 相比,风险比随随访时间呈比例变化。
在急性心脏疾病患者中,轻度甲状腺功能异常与死亡率增加相关,且在整个随访期间保持不变。